BioNTech commercial revenues by type 2025 | �ֲ��ýapp��°汾

Commercial revenues of BioNTech SE from 2022 to 2025, by type (in million euros)

BioNTech commercial revenues by type 2022-2025

Last update:

Jul 20, 2026

Author:

�ֲ��ýapp��°汾 Research Department

Regions:

Worldwide, Germany

Survey time period:

From 01/01/2022 to 31/12/2025

In 2025, total commercial revenues of biotech company BioNTech SE stood at billion euros, of which billion were due to the COVID-19 vaccine.

On November 9th, 2020, German biotech company BioNTech, in cooperation with U.S. pharma giant Pfizer, was the first to announce a proven COVID-19 vaccine to be ready for mass production by year-end.

We’re happy to help

Get in touch with us for additional information

Feel free to contact us anytime. We will respond to your inquiry as quickly as possible.

Get in touch

�ֲ���ýapp���°汾

Commercial revenues of BioNTech SE from 2022 to 2025, by type (in million euros)

Get in touch with us for additional information

�ֲ��ýapp��°汾